Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Quince Therapeutics and keeping the price target at $6.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jason McCarthy’s rating is based on the promising developments surrounding Quince Therapeutics’ lead product candidate, eDSP, which is currently undergoing a pivotal Phase 3 NEAT study for Ataxia-Telangiectasia. The study has completed enrollment and is expected to deliver top-line results in the first quarter of 2026, a critical milestone for the company. McCarthy highlights the potential success of the study, given the historical data supporting the efficacy and safety of eDSP, which could lead to a New Drug Application filing in the second half of 2026.
Furthermore, Quince’s innovative AIDE technology platform, which underpins eDSP, offers a unique point-of-care approach that enhances the delivery of dexamethasone, potentially expanding its application to other indications like Duchenne muscular dystrophy. The company’s financial position, with sufficient cash reserves to support operations through the Phase 3 data event, also contributes to the optimistic outlook. McCarthy’s valuation model, incorporating risk adjustments and a discount rate, supports a 12-month price target of $6.00, reinforcing the Buy recommendation.
In another report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $10.00 price target.